LONDON - Graft Polymer (UK) Plc (LON:GPL) has announced plans to change its corporate identity to Solvonis Therapeutics Plc, a move that requires shareholder approval at the upcoming general meeting on January 6, 2025. The proposed name reflects the company's strategic emphasis on developing treatments for mental health and substance use disorders, particularly focusing on trauma-related conditions such as PTSD.
The rebranding initiative aligns with the company's ongoing efforts to expand its intellectual property and co-develop therapeutic solutions through joint ventures, strategic partnerships, and acquisitions. The Board of Directors has unanimously recommended that shareholders support the change, which they believe is in the best interests of the company and its stakeholders.
In conjunction with the rebranding news, Graft Polymer reported continued progress in its collaboration with Awakn on the Aminoindane New Chemical Entity (NCE) program. The initial study results, a joint effort with Eurofins Discovery (NASDAQ:WBD) and the University of Nottingham, are anticipated to be released shortly, marking a significant milestone in the program's advancement.
The collaboration has maintained its momentum despite Charnwood Discovery, Awakn's synthesis partner, being acquired by Concept Life Sciences on November 5, 2024. Awakn has confirmed that the partnership will proceed smoothly with Concept Life Sciences, which will take over the synthesis activities necessary for the Aminoindane NCE program's development.
The upcoming general meeting, where shareholders will vote on the proposed name change, will be held at Eccleston Yards in London. The notice for the meeting, including more details, has been sent to shareholders and is available on the company's website.
This report is based on a press release statement by Graft Polymer (UK) Plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.